Publications & Talks
Our Research / Publications & Talks
Defining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD.
McHutchison CA (presenter), Abrahams S, Wuu J, Cosentino S, Benatar M. Defining mild cognitive and behavioural impairment in pre-symptomatic ALS/FTD. ePoster presentation at the 33rd International Symposium on ALS/MND (Virtual), Dec 6-9, 2022.
Mild Motor Impairment and Prodromal Disease Markers.
Benatar M (plenary speaker). Mild Motor Impairment and Prodromal Disease Markers. Platform presentation at the 33rd International Symposium on ALS/MND (Virtual), Dec 6-9, 2022.
Patterns of longitudinal cognitive and behavioural changes in ALS/MND.
McHutchison CA (presenter), Wuu J, Abrahams S, Benatar M. Patterns of longitudinal cognitive and behavioural changes in ALS/MND. ePoster presentation at the 32nd International Symposium on ALS/MND (Virtual), Dec 7-10, 2021.
Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis.
Statland J (presenter), Karanevich A, Wuu J, Swenson A, Barohn RJ, Schule R, Jackson C, Ravits J, Granit V, McCauley J, Zuckner S, Caress J, Trivedi J, Maiser S, Walk D, Pioro E, McMillan C, Elman L, Katz J, Heckmann J, Burns T, So Y, Wu G, Rampersaud E, Rademakers R, van Blitterswijk M, Taylor JP, Benatar M, on behalf of the CReATe Consortium. Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis.
Statland J (presenter), Karanevich A, Wuu J, Swenson A, Barohn RJ, Schule R, Jackson C, Ravits J, Granit V, McCauley J, Zuckner S, Caress J, Trivedi J, Maiser S, Walk D, Pioro E, McMillan C, Elman L, Katz J, Heckmann J, Burns T, So Y, Wu G, Rampersaud E, Rademakers R, van Blitterswijk M, Taylor JP, Benatar M, on behalf of the CReATe Consortium. Genotype phenotype correlation and longitudinal study of hereditary spastic paraplegia and primary lateral sclerosis. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS.
Gray E (presenter), AG Thompson, Wuu J, Pelt J, Talbot K, Benatar M, Turner MR. Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS.
Gray E (presenter), AG Thompson, Wuu J, Pelt J, Talbot K, Benatar M, Turner MR. Chitotriosidase level and activity rises in the pre- and early symptomatic phases of ALS. Platform presentation at the 30th International Symposium on ALS/MND, Perth, Australia, Dec 4-6, 2019.
Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers.
McMillan CT (presenter), Wuu J, Cook P, Olm C, Duda J, Gee J, Clayman CE, Elman L, McCluskey L, Irwin DJ, Grossman M, Benatar M. Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers.
McMillan CT (presenter), Wuu J, Cook P, Olm C, Duda J, Gee J, Clayman CE, Elman L, McCluskey L, Irwin DJ, Grossman M, Benatar M. Baseline and longitudinal volumetric changes associated with presymptomatic C9ORF72 repeat expansion carriers. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
When does ALS begin? Insights from serum and CSF neurofilament light and heavy.
Benatar M (presenter), Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. When does ALS begin? Insights from serum and CSF neurofilament light and heavy. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
When does ALS begin? Insights from serum and CSF neurofilament light and heavy.
Benatar M (presenter), Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A. When does ALS begin? Insights from serum and CSF neurofilament light and heavy. Platform presentation at the 29th International Symposium on ALS/MND, Glassgow, UK, Dec 7-9, 2018.
Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease.
Benatar M (presenter), Wuu J, Lombardi V, Andersen PM, Malaspina A. Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease. Platform presentation at the 28th International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.
Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease.
Benatar M (presenter), Wuu J, Lombardi V, Andersen PM, Malaspina A. Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease. Platform presentation at the 28th International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.
Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development.
Rogers ML (presenter), Shepheard S, Wuu J, Andersen P, Schultz D, Benatar M. Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development. Platform presentation at the International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.
Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development.
Rogers ML (presenter), Shepheard S, Wuu J, Andersen P, Schultz D, Benatar M. Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development. Platform presentation at the International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.